Tonix Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Tonix Pharmaceuticals CEO Seth Lederman will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025. The company recently gained FDA approval for Tonmya, a non-opioid analgesic for fibromyalgia, and secured a $34 million contract with the Department of Defense for TNX-4200 development. Tonix's diverse pipeline focuses on central nervous system disorders, immunology, and infectious diseases.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, has announced that Seth Lederman, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 1:35 PM ET. The event will provide an opportunity for investors and industry professionals to gain insights into Tonix's recent developments and future prospects.

The fireside chat will be webcast and available on the Events page of the Investors section of Tonix's website at [https://ir.tonixpharma.com/news-events](https://ir.tonixpharma.com/news-events). A replay of the webcast will be accessible for 90 days following the event.

Tonix recently received FDA approval for Tonmya™, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. The company also markets two treatments for acute migraine in adults and has a robust pipeline focused on central nervous system (CNS) disorders, immunology, immuno-oncology, and infectious diseases.

Tonix's development portfolio includes TNX-102 SL, which is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154). Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, and TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments.

Tonix owns and operates a state-of-the-art infectious disease research facility in Frederick, Md. The company has also secured a $34 million contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to five years to develop TNX-4200.

The fireside chat is expected to provide valuable insights into Tonix's strategic direction, recent achievements, and future prospects, particularly in the areas of CNS disorders, immunology, and infectious diseases.

References:
[1] https://ir.tonixpharma.com/news-events/press-releases/detail/1586/tonix-pharmaceuticals-to-participate-in-a-fireside-chat-at